SCHEMBL451772

SCHEMBL451772

N[C@@H](Cc1ccc(OC(=O)O)cc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.62
PTGS1 P23219 3/20 0.61
ALPI P09923 1/20 0.61
PKM P14618 1/20 0.61
XIAP P98170 1/20 0.61
PTPN1 P18031 2/20 0.60
ITGB3 P05106 1/20 0.59
ITGA2B P08514 1/20 0.59
HIF1A Q16665 4/20 0.53
ALOX15 P16050 3/20 0.53
KDM4E B2RXH2 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
USP2 O75604 1/20 0.53
EGFR P00533 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTR2A P28223 1/20 0.53
PTGS2 P35354 1/20 0.53
RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL450849 0.91 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL671002 0.91 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL22645606 0.91 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1639831 0.88 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4287070 0.85 ITGB3 (0.58) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28447519 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL27971967 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1537419 0.85 ITGB3 (0.58) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4410810 0.85 SLC7A5 (0.66) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL3261478 0.85 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120132207-A Electric controlled release separable microneedle patch and drug delivery device 成都邦迈医创科技有限公司 2025-06-13 CN claimed
WO-2025084687-A1 DRUG DELIVERY DEVICE KIT FOR IN VIVO IMPLANTATION 투바이오스 주식회사 2025-04-24 WO claimed
US-12233229-B2 Perforated plate microstructure module INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2025-02-25 US claimed
EP-4373419-A1 FIBER-REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS WITH DEFORMABLE PROTRUSIONS AND METHODS OF USE THEREOF Ossio Ltd. (IL) 2024-05-29 EP claimed
WO-2024105655-A1 FIBER-REINFORCED ORTHOPEDIC COMPRESSION STAPLE Ossio Ltd. (IL) 2024-05-23 WO claimed
US-20240115775-A1 CONTINUOUS-FIBER REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS OSSIO INC. 2024-04-11 US claimed
US-11883508-B2 Method for culturing 3-dimensional lung cancer organoid and method for preparing patient-derived xenograft animal model using same ONCOCLEW CO., LTD. (KR) 2024-01-30 US claimed
EP-3628249-B1 CONTINUOUS-FIBER REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS OSSIO LTD (IL) 2023-12-06 EP claimed
WO-2023195666-A1 DRUG INJECTION DEVICE 서울대학교산학협력단 2023-10-12 WO claimed
CN-116831975-A Microneedle patch for inducing immune tolerance to treat rheumatoid arthritis 四川大学 2023-10-03 CN claimed
WO-2016035088-A1 ANISOTROPIC BIOCOMPOSITE MATERIAL, MEDICAL IMPLANTS COMPRISING SAME AND METHODS OF TREATMENT THEREOF RESORBIUM LTD. (IL) 2016-03-10 WO claimed
US-20160038641-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2016-02-11 US claimed
EP-2398511-B1 MEDICAL DEVICE AND METHOD FOR MAKING THE SAME SOFRADIM PRODUCTION (FR) 2013-04-17 EP claimed
US-20120021217-A1 FIBERS WITH AN ACTIVATED SURFACE AND METHOD OF MAKING SAME BY EXTRUSION COVIDIEN LP 2012-01-26 US claimed
EP-2314328-A2 Reactive surgical implant Tyco Healthcare Group LP (US) 2011-04-27 EP claimed
WO-2010095057-A1 FIBERS WITH AN ACTIVATED SURFACE AND METHOD OF MAKING SAME BY EXTRUSION SOFRADIM PRODUCTION (FR) 2010-08-26 WO claimed
US-20100104608-A1 REACTIVE SURGICAL IMPLANT TYCO HEALTHCARE GROUP LP (US) 2010-04-29 US claimed
WO-2007005180-A9 METHOD FOR ENHANCING ENGRAFTMENT OF THERAPEUTIC CELLS AT A TARGET SITE ADVANCED CARDIOVASCULAR SYSTEM (US) 2007-04-05 WO claimed
WO-2007005180-A2 METHOD FOR ENHANCING ENGRAFTMENT OF THERAPEUTIC CELLS AT A TARGET SITE ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2007-01-11 WO claimed
US-20070003528-A1 Intracoronary device and method of use thereof ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100104608-A1 REACTIVE SURGICAL IMPLANT ECPAS, STIM2, STUB1 SLC7A5 4504/4885PTGS1 897/4885ALPI 3381/4885
US-20160038641-A1 COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR BMP2, BMP4, BMP6 SLC7A5 2466/4885PTGS1 435/4885ALPI 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.